Prostate Cancer Mortality Risk Factors After Brachytherapy for Gleason 3+4 Identified
Addition of ADT to brachytherapy may not improve cancer-specific survival among some men with Gleason 3+4 prostate cancer.
Diagnosis & Disease Information
Brachytherapy Beneficial in Low-Risk Prostate Cancer, Study Finds
Among men with low-risk prostate cancer, the likelihood of biochemical failure is lower among patients who undergo low-dose-rate brachytherapy vs radical prostatectomy, data suggest.
Single-Dose Brachytherapy Effective for Prostate Cancer
Two-year and three-year biochemical progression-free survival rate of 100 percent for low-risk disease
Prostate Cancer Mortality Lowest With Radical Prostatectomy
In a study with a follow-up period of 18 years, men treated with any other modality but radical prostatectomy had higher prostate cancer death risks.
Prostate Cancer Brachytherapy Outcomes Linked to PSADT
Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.
Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk PCa
The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.
Brachytherapy Alone May Be Sufficient for More Risky PCa Cases
The investigators observed no difference in mortality between BT alone and BT plus ADT and/or EBRT supplemental therapy.
LDR Brachytherapy for Prostate Cancer Offers Excellent Survival
In a study, the 17-year prostate cancer-specific and biochemical failure-free survival rates were 97% and 79%, respectively.
Surgery vs Radiation for High-Risk Prostate Cancer
Physicians who treat patients with high-risk prostate cancer remain uncertain as to the optimal treatment approach, in part due to difficulty in interpreting study data.
Brachytherapy + EBRT for High-Risk PCa Offers ‘Excellent’ Outcomes
Biochemical failure and prostate cancer-specific mortality rates were 13.3% and 4.9% at 10 years, respectively.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...